Portfolio

Specialty pharmaceutical company, focusing on identifying, developing, and commercializing topical drugs to address various needs in dermatology.

Specialty pharmaceutical company engaged in the development, commercialization and marketing of over-the-counter and prescription drugs for the treatment of respiratory disorders

Biopharmaceutical company that develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of infectious diseases

Provider of bioanalytical testing equipment to the pharmaceutical industry

Biopharmaceutical company developing human enzyme therapeutics for rare genetic diseases

Women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products

Biopharmaceutical company developing desensitization treatments for food allergies

Medical device platform building a diversified portfolio of emerging medical device companies

Biopharmaceutical company engaged in the development and commercialization of anti-cancer therapeutics

Biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat oncology, autoimmune and inflammatory diseases

Antios Therapeutics is a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure viral diseases. Antios is currently developing ATI-2173, aiming to provide chronic hepatitis B-infected patients with a curative combination regimen.

Oncology drug development company focused on novel therapeutics for prostate and breast cancer

Manufacturer of active pharmaceutical ingredients and late state intermediates for the pharmaceutical industry

Biotechnology company developing cancer immunotherapies targeting the adenosine and other oncology pathways

Biopharmaceutical company dedicated to the discovery and development of novel small-molecule therapeutics to treat debilitating cardiac, muscular and neurological disorders

Biotechnology company developing immuno-oncology therapies in combination with standard of care or emerging immunotherapies

Endocrine-focused biopharmaceutical company developing long-acting human growth hormone for the treatment of pediatric growth hormone deficiency

Biotechnology company focused on the development of novel treatments for cancer

Biotechnology company developing novel oncology therapeutics based on a deep understanding of the human immune response

Biotechnology company developing gene therapy-based treatments in several serious, rare diseases

Specialty pharmaceutical company that develops and markets pharmaceutical products for urology and sexual health

Contract research organization that provides GLP complaint drug development services for biotechnology and pharmaceutical firms, and government agencies

Biotechnology company developing lentiviral-based gene therapies to treat lysosomal storage disorders (LSDs)

Specialty pharmaceutical company focused on the treatment of gastrointestinal disorders

Specialty pharmaceutical company focused on development and commercialization of dermatology drugs

Bicara Therapeutics developing first-in-class biologics engineered to combine the precision of well validated, tumor-targeting antibodies with the power of tumor microenvironment modulators.

Biotechnology company focused on the development and commercialization of drugs to treat oncology and infectious disease

Biopharmaceutical company developing treatments for orphan neurologic indications and other areas of large unmet medical needs

Biomea Fusion is a preclinical-stage biopharmaceutical company focused on the discovery and development of irreversible small molecules to treat patients with genetically defined cancers. Leveraging its extensive expertise in irreversible binding chemistry and development, the Company built its proprietary FUSION System discovery platform to advance a pipeline of novel irreversible, small molecule therapies. The lead product candidate, BMF-219, is an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. Biomea Fusion’s goal is to utilize its capabilities and platform to become a leader in developing irreversible small molecules in order to maximize the depth and durability of clinical benefit when treating various cancers.

Orphan disease drug platform with a robust portfolio of transformative drug programs that address rare diseases across oncology, cardiology, dermatology, neurology and endocrinology

CalciMedica, Inc. is a clinical stage biotechnology company focused on developing therapies for life-threatening inflammatory diseases with high unmet need. CalciMedica’s proprietary technology targets the inhibition of CRAC (calcium release-activated calcium) channels designed to modulate the immune response and protect against tissue cell injury. The Company is evaluating its lead candidate Auxora, a proprietary intravenous small molecule CRAC channel inhibitor in studies for acute pancreatitis (AP) and acute kidney injury (AKI).

Biotechnology company developing drugs for the treatment and prevention of cardiovascular diseases

Provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products

Drug discovery and development company focused on infectious diseases and the treatment of drug-resistant bacteria

Biopharmaceutical company dedicated to discovering, developing and commercializing novel, oral antivirals in areas of high unmet medical need

Drug discovery and development company focused on devastating fungal infections that often complicate cancer and transplant treatments

Biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents

Specialty pharmaceutical company that develops and markets proprietary medical therapies to the dermatology market

Cosmetics company that manufactures and sells mineral-based products

COMPASS Pathways is a mental health biotechnology company pioneering the development of a new model of psilocybin treatment, in which their proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support.

Specialty pharmaceutical company focused on the treatment of OFF episodes in Parkinson’s disease

Biopharmaceutical company focused on the development of targeted immunotherapies with a VLP B-cell vaccines platform and ongoing preclinical development programs based on the platform

Specialty biopharmaceutical company focused on bringing innovative and differentiated medical dermatology products to dermatologists and their patients

Pharmaceutical company focused on the development and commercialization of differentiated therapeutic solutions for physicians and providers to advance patient care in infectious disease and acute illnesses

Medical device company committed to providing hearing impaired patients a hearing solution that is designed to change the current standard of care for sound performance.

Biopharmaceutical company developing therapies to treat transthyretin amyloidosis (ATTR), primarily in the heart

Elevation Oncology is a clinical-stage oncology company developing targeted therapies for genetically driven cancers. Elevation's lead product candidate, seribantumab, a HER3 monoclonal antibody, is enrolling a Phase 2 registrational trial for NRG1 fusion-driven cancers.

Drug discovery and development company focused on therapies that prevent, treat and reverse cardiovascular and metabolic diseases

Antifungal drug discovery and development company focused on novel therapies to treat life threatening invasive fungal infections

Garuda Therapeutics seeks to create a world that eliminates the dependency on donor or patient cells for blood stem cell transplants. Garuda's platform technology for generating off-the-shelf, self-renewing blood stem cells is poised to provide patients with rapid and broad access to consistent, durable, HLA-compatible and transgene-free blood stem cell therapies. Like bone marrow transplants, Garuda's technology could provide potentially curative therapies for more than 70 diseases.

Biopharmaceutical company developing novel therapies to improve the lives of patients with serious blood-based disorders

Biopharmaceutical company targeting hormone pathways to treat stress urinary incontinence (SUI) in women

Biopharmaceutical company developing and commercializing innovative drugs to address unmet needs for patients with sleep and CNS disorders

Anti-cancer drug targeting B-cell malignancies

Biopharmaceutical company dedicated to discovering, developing and delivering best-in-class medicines to patients with difficult-to-treat diseases

Biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver and intestinal diseases utilizing our proprietary bile acid chemistry

Commercial stage drug-device company committed to improving the quality of life for patients with ear, nose and throat conditions

Leader in next-generation femtosecond laser technology for refractive cataract surgery

Medical technology company specializing in developing, manufacturing and marketing endovascular stent-grafts that address significant unmet needs in the repair of aortic aneurysms

Biotechnology company developing targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations

Specialty pharmaceutical company developing new therapies based on proprietary drug particle and inhalation technologies

Biotechnology company developing next-generation T cell-based immunotherapies for cancer

Medical Knowledge Group is comprised of best-in-class medical communications, health care consulting, and data analytics companies. Guided by strategic insight, creative innovation, and medical acumen, MKG companies specialize in distinct service areas within the health care marketing and communications sector.

Oncology company focused on the clinical development of novel therapies for cancer

Biopharmaceutical company developing an oral therapy for the treatment of chronic pruritus associated with various conditions and chronic cough

Medical device company focused on developing products for dermatologic medical conditions

Monte Rosa Therapeutics is a biotechnology company developing molecular glues to degrade disease-causing proteins. The company has developed a platform to rationally design small molecules that reprogram ubiquitin ligases to eliminate disease drivers previously deemed undruggable. The company’s drug discovery platform combines diverse and proprietary chemical libraries of small molecule protein degraders with in-house proteomics, structural biology, machine learning-based target selection and computational chemistry capabilities to predict and obtain protein degradation profiles.

Biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders

Biopharmaceutical company developing new antibiotics to treat infectious diseases

Specialty pharmaceutical company developing extended release OTC and prescription products for children and adults

Biotechnology company focused on drugs to treat lysosomal storage diseases

Nuvation Bio is a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio’s portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-868 (BET), and NUV-1511 (DDC). Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world’s leading prostate cancer medicines. Nuvation Bio has offices in New York, San Francisco, and Shanghai.

Biopharmaceutical company developing novel therapeutics in women's health for the treatment of symptoms associated with endometriosis and uterine fibroids

Ophthalmic drug delivery company with platform technology to facilitate the treatment of major sight-threatening eye diseases and conditions

Biopharmaceutical company engaged in the discovery, development and commercialization of antibiotics to save lives and alleviate suffering

Biotechnology company developing topical therapeutics targeting rare dermatological diseases

Specialty pharmaceutical company primarily focused on the sales, marketing and development of branded pharmaceutical products

Provider of research and development services for pharmaceutical and biotechnological industries worldwide

Developer and manufacturer of allergenic extracts and other products for the treatment and prevention of allergy

Biopharmaceutical company developing next-generation CAR-T therapies for hematological cancers and solid tumors.

Developer of a fluid-controlled intraocular lens

Specialty pharmaceutical company developing, manufacturing and marketing prescription and consumer dermatology products

Biopharmaceutical company developing and marketing human milk-based nutritional products for premature infants in the neonatal intensive care unit

Biopharmaceutical company focused on the discovery and development of first-in-class therapies to treat central nervous system disorders of System XC-

Clinical-stage biopharmaceutical company, focuses on discovering and developing peptide-based new chemical entities to address significant unmet medical needs in inflammatory bowel diseases

Contract pharmaceutical research and sales organization

Reneo is a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). Reneo is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes. REN001 has been shown to increase transcription of genes involved in mitochondrial function and increase fatty acid oxidation and may increase production of new mitochondria.

Molecular diagnostics company focused on the development and commercialization of molecular assay technologies for the detection of foodborne pathogens

Biopharmaceutical company focused on developing drugs for the treatment of estrogen receptor dependent breast cancer

Ophthalmic-focused biopharmaceutical company engaged in the discovery, development and commercialization of products for the protection and preservation of eyesight

Specialty pharmaceutical company focused on development and commercialization of dermatology drugs and cosmeceuticals

Biopharmaceutical company engaged in the discovery, acquisition, development and commercialization of proprietary drug therapeutics for addressing significant unmet medical needs

Medical device company that is focused on developing minimally invasive technologies that improve the quality of life for patients with nasal obstruction

Spruce is a clinical stage biopharmaceutical company developing therapeutics for rare endocrine diseases. Spruce's lead product, tildacerfont, is in late-stage development for classic congenital adrenal hyperplasia (CAH).

Spyre Therapeutics is developing potential best-in-class antibodies, rational therapeutic combinations, and precision immunology approaches with the goal of creating Inflammatory Bowel Disease (IBD) therapies with uncompromising efficacy and convenience.

Biotechnology company developing a pipeline of cancer therapies, including a precision oncology asset for genetically-defined acute leukemias.

Biopharmaceutical company focused on the development of novel therapies based on the natural human hormone, uroguanylin, to treat gastrointestinal (GI) diseases and disorders

In vitro diagnostics company that has developed a technology platform that offers a rapid, sensitive and simple alternative to existing diagnostic methodologies

Talaris Therapeutics, Inc., formerly Regenerex, is a late-clinical stage biotechnology company that is developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe auto-immune and immune-mediated disorders. Talaris was founded on technology discovered and developed by Dr. Suzanne Ildstad and operates its own cell processing facility in Louisville, KY. Talaris is backed by leading life sciences investors Blackstone Life Sciences, Longitude Capital and Qiming Venture Partners USA and maintains corporate offices in Boston, MA and Louisville, KY.

Specialty pharmaceutical company focused on developing and commercializing treatments primarily for the pediatric and dermatology markets.

Medical device company that is focused on the development and commercialization of manual and robotic assisted surgical systems for minimally invasive surgery

Medical device company developing and commercializing at-home, light-based skincare products

UK-based biopharmaceutical company focused on the development of innovative prescription medicines to treat respiratory diseases with significant medical unmet needs

Endocrine-focused biopharmaceutical company developing novel long-acting recombinant human growth hormone for growth hormone deficiency

Medical device company developing advanced radiation therapy technology for the treatment of cancer

Precision oncology company focused on the treatment and prevention of virus-associated cancers

Biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes, sleep apnea and sexual health

Wugen, Inc., is a clinical-stage biotechnology company developing a pipeline of off-the-shelf memory NK and CAR-T cell therapies to treat a broad range of hematological and solid tumor malignancies. Memory NK cells are hyper-functional, long-lasting immune cells that have evolved to attack cancer and respond to infection. Wugen is harnessing the power of this rare cell population by using its proprietary technologies to create WU-NK-101, currently in development for acute myelogenous leukemia (AML) and solid tumors. Wugen is also advancing WU-CART-007, an allogeneic CAR-T currently in development for T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (LBL).

Biopharmaceutical company focused on novel products that address serious unmet medical needs in the hospital

Medical technology company focused on developing and commercializing products utilizing a controlled cooling technology platform for non-invasive fat reduction

Biopharmaceutical company developing a novel patch formulation of zolmitriptan for the treatment of acute migraine